PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|October 2, 2014
Explore state-of-the-art clinical filling in Chicago
Author(s)Vetter Pharma
Parenteral drug development is complex, costly, and subject to many levels of risk during the clinical phases. Only a few drug products ever make it to phase III, through approval, and on into commercial manufacturing. Given the numerous hurdles that exist, realizing the drug development process efficiently during all phases has become ever more important. And, having the right partner on board to support the project is critical in preparing a valuable drug package that can be used for either further product development and commercialization, or for a successful out-licensing deal.
Explore state-of-the-art clinical filling in Chicago
Parenteral drug development is complex, costly, and subject to many levels of risk during the clinical phases. Only a few drug products ever make it to phase III, through approval, and on into commercial manufacturing. Given the numerous hurdles that exist, realizing the drug development process efficiently during all phases has become ever more important. And, having the right partner on board to support the project is critical in preparing a valuable drug package that can be used for either further product development and commercialization, or for a successful out-licensing deal.
The podcast will showcase Vetter´s service portfolio as a company in general, and its offering in the development service area in detail. In addition, this podcast will focus on the companies` capabilities in its Chicago development service site, including its customer base. An informative case study highlighting the critical expertise needed in today´s drug development environment will be presented.
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.